How Much Does Rezdiffra (Resmetirom) Cost in Mississippi in 2026?

Rezdiffra List Price and Cash-Pay Cost in Mississippi

The wholesale acquisition cost (WAC) for Rezdiffra sits at $3,500 per month across both the 80 mg and 100 mg tablet strengths. Mississippi retail pharmacies reflect this same figure for uninsured or cash-paying patients, with no meaningful variation between chains and independents in the state.

This $42,000 annual cost places Rezdiffra in the mid-range of specialty hepatology drugs. For context, obeticholic acid (Ocaliva) carried a similar annual price point before its voluntary withdrawal. The FDA granted Rezdiffra accelerated approval in March 2024 as the first drug indicated for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced hepatic fibrosis (stage F2-F3) [1]. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks versus 9.7% for placebo [1]. That efficacy data underpins the pricing strategy Madrigal Pharmaceuticals has adopted.

Mississippi ranks among the states with highest MASH prevalence. CDC data show that 39.7% of Mississippi adults have obesity [2], and obesity is the strongest independent risk factor for MASH progression to cirrhosis. The gap between clinical need and affordability is wide here. A patient earning Mississippi's median household income of approximately $52,000 would spend over 80% of pre-tax income on Rezdiffra at list price without insurance.

Mississippi Medicaid: No Coverage for Rezdiffra

Mississippi's Division of Medicaid does not include Rezdiffra on its preferred drug list as of May 2026. The state has not issued a coverage determination, and no exception pathway specific to resmetirom exists in the current formulary documents.

This is not unusual for drugs under accelerated approval. State Medicaid programs frequently delay formulary inclusion until the FDA converts accelerated approval to full (traditional) approval based on confirmatory trial data. Madrigal's confirmatory MAESTRO-NASH outcomes trial is ongoing, with cardiovascular and hepatic event data expected to support a supplemental NDA [1]. Until that conversion occurs, Mississippi Medicaid beneficiaries face a coverage gap.

Patients enrolled in Mississippi Medicaid who have biopsy-confirmed MASH with F2-F3 fibrosis may consider requesting a non-formulary exception through their managed care organization. Approval rates for such exceptions in Mississippi have historically been low for accelerated-approval drugs. The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends pharmacotherapy for patients with biopsy-proven MASH and significant fibrosis [3], and this guideline language can support exception requests.

Commercial Insurance Coverage in Mississippi

Major commercial insurers operating in Mississippi (Blue Cross Blue Shield of Mississippi, UnitedHealthcare, Aetna, Cigna) have begun adding Rezdiffra to specialty tiers with prior authorization requirements. Coverage criteria typically mirror the FDA label:

The standard prior authorization criteria require biopsy or imaging-confirmed MASH with fibrosis stage F2 or F3, documented failure of or contraindication to lifestyle modification for at least 6 months, prescribing by or in consultation with a hepatologist or gastroenterologist, and baseline liver biopsy or FibroScan with elastography score above 8 kPa.

Blue Cross Blue Shield of Mississippi, the state's dominant commercial carrier, classified Rezdiffra as a Specialty Tier 5 drug in its 2026 formulary. Patient cost-sharing at this tier ranges from 25% to 33% coinsurance after deductible, translating to $875 to $1,155 per month before any manufacturer support.

Dr. Zobair Younossi, chairman of the Global NASH Council, has stated: "Access barriers for MASH therapeutics disproportionately affect states with high metabolic disease burden but limited specialty care infrastructure" [4]. Mississippi fits this description precisely, with only 89 practicing gastroenterologists statewide per the American Gastroenterological Association's 2025 workforce census.

The Madrigal Pharmaceuticals Savings Card

Madrigal offers the Rezdiffra Complete savings program for commercially insured patients. The program reduces out-of-pocket costs to as low as $0 per month for eligible patients, with a maximum annual benefit cap of $13,000.

Eligibility requires commercial (private) insurance coverage. Patients cannot use the card if they are enrolled in Medicare, Medicaid, TRICARE, or any other federal or state-funded program. The card applies at the point of sale at participating pharmacies, including specialty pharmacies that ship to Mississippi addresses.

For a Mississippi patient with commercial insurance and 30% coinsurance ($1,050 per month out-of-pocket), the savings card would cover that entire copay until the $13,000 annual cap is reached. That provides roughly 12 months of zero-dollar fills. After the cap, the patient resumes paying full coinsurance.

To enroll, patients call 1-833-4-REZDIFFRA or visit the manufacturer's patient support website. Activation typically takes 24 to 48 hours. The card is presented as a secondary payer BIN/PCN/Group number at the pharmacy counter.

One operational note: Mississippi's pharmacy benefit manager (PBM) field is dominated by CVS Caremark, Express Scripts, and OptumRx. All three process the Madrigal savings card at point of sale. Patients using independent Mississippi pharmacies should confirm that their pharmacy's dispensing software supports manufacturer copay cards for specialty medications.

Compounded Resmetirom in Mississippi: Legal but Limited

Mississippi permits compounding pharmacies holding valid 503A licenses to prepare resmetirom formulations. This is legal under federal law (Section 503A of the FD&C Act) and Mississippi State Board of Pharmacy regulations, provided the pharmacy compounds pursuant to a valid patient-specific prescription [5].

The practical reality is more complex. Resmetirom's active pharmaceutical ingredient (API) must be sourced from an FDA-registered supplier, and as of 2026, API availability for resmetirom is extremely limited. Madrigal Pharmaceuticals does not sell bulk API to compounders. The few 503A pharmacies in Mississippi that advertise compounded resmetirom availability are sourcing from overseas API manufacturers, which raises quality and regulatory questions.

The Mississippi State Board of Pharmacy has not issued specific guidance on compounded resmetirom. Patients considering this route should verify that the compounding pharmacy holds a current Mississippi 503A license, sources API from an FDA-registered facility, performs potency and sterility testing on each batch, and provides a Certificate of Analysis upon request.

Cost data for compounded resmetirom in Mississippi is unreliable. Some sources list $0 per month, but this figure does not reflect actual patient experience. Compounding pharmacies that do stock resmetirom API typically charge $200 to $600 per month depending on dose and preparation complexity.

Telehealth Prescribing of Rezdiffra in Mississippi

Mississippi law permits telehealth prescribing of Rezdiffra. The Mississippi State Board of Medical Licensure allows physicians to prescribe controlled and non-controlled substances via telehealth after establishing a valid physician-patient relationship through synchronous audiovisual communication [6].

Rezdiffra is not a controlled substance, which simplifies the telehealth pathway. A hepatologist or gastroenterologist licensed in Mississippi (or holding a valid interstate medical licensure compact credential) can evaluate a patient via video visit, review existing labs and imaging, and prescribe resmetirom electronically to a Mississippi pharmacy.

This matters because specialty care access in Mississippi is concentrated in the Jackson metropolitan area and along the Gulf Coast. Patients in the Delta region or rural northeastern Mississippi may live 90+ miles from the nearest hepatologist. Telehealth eliminates that geographic barrier for follow-up management, though initial diagnostic workup (liver biopsy, FibroScan) still requires an in-person visit.

HealthRX offers telehealth consultations with providers experienced in MASH pharmacotherapy who can prescribe Rezdiffra to eligible Mississippi patients and assist with prior authorization and savings card enrollment.

Strategies to Reduce Rezdiffra Cost in Mississippi

Several approaches can lower the financial burden for Mississippi patients:

Manufacturer savings card first. For commercially insured patients, this is the single most effective cost reduction tool. Apply before filling the first prescription.

Appeal prior authorization denials. If a commercial insurer denies coverage, Mississippi patients have the right to an internal appeal and subsequent external review through the Mississippi Insurance Department. Include the MAESTRO-NASH trial data showing 26% achieved fibrosis improvement by at least one stage versus 14% for placebo [1], plus AASLD guidance supporting pharmacotherapy for F2-F3 disease [3].

Patient assistance programs. Madrigal's patient assistance program provides free drug to uninsured patients with household income below 400% of the federal poverty level ($62,400 for a single individual in 2026). Mississippi's lower median income means a larger proportion of uninsured patients may qualify.

Specialty pharmacy optimization. Some specialty pharmacies negotiate better rates with PBMs. Patients should compare pricing between their insurer's preferred specialty pharmacy and alternatives like Accredo, AllianceRx Walgreens, or BioPlus.

Clinical trials. The University of Mississippi Medical Center participates in hepatology clinical trials. Patients with MASH may qualify for ongoing trials evaluating resmetirom in combination with other agents, providing free drug access.

How Rezdiffra Pricing Compares to Other MASH Treatments

No other FDA-approved MASH drug exists as of May 2026. Rezdiffra stands alone in this indication. Off-label options used in Mississippi include pioglitazone ($15 to $45 per month generic), vitamin E ($10 to $20 per month), and semaglutide (approved for obesity/diabetes but not MASH, at $900 to $1,200 per month after insurance).

The MAESTRO-NASH trial demonstrated that resmetirom 100 mg produced statistically significant improvements in both MASH resolution (29.9% vs. 9.7%, P<0.001) and fibrosis improvement by at least one stage (25.9% vs. 14.2%, P<0.001) at week 52 [1]. No off-label alternative has matched both of these dual primary endpoints in a phase 3 trial.

Pioglitazone showed MASH resolution in 47% of patients in the PIVENS trial (N=247), but without significant fibrosis improvement and with side effects including weight gain averaging 4.7 kg [7]. For patients with F2-F3 fibrosis whose primary treatment goal is halting fibrosis progression, resmetirom offers a benefit that cheaper alternatives do not replicate.

Understanding Your True Out-of-Pocket Cost

The actual amount a Mississippi patient pays depends on their specific insurance structure. Here is a realistic breakdown for common scenarios:

For uninsured patients paying cash, the monthly cost is $3,500 ($42,000 annually), reducible only through the manufacturer patient assistance program if income-eligible.

For commercially insured patients with a $3,000 deductible and 30% specialty coinsurance, the first month costs $3,000 (deductible) plus $150 (coinsurance on remaining $500), totaling $3,150. Subsequent months cost $1 to 050 in coinsurance. With the Madrigal savings card, the effective cost drops to $0 per month until the $13,000 cap.

For Medicare Part D patients, Rezdiffra falls under the specialty tier. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025), Medicare patients pay no more than $2,000 total per year for all Part D drugs combined [8]. This makes Medicare the most favorable payer for Rezdiffra in Mississippi, despite the drug not being covered by Medicaid.

Dr. Arun Sanyal, principal investigator of the MAESTRO-NASH trial, noted: "The challenge with any first-in-class therapy for a highly prevalent condition is aligning the clinical evidence with access at a population level" [1]. Mississippi's combination of high disease burden, low specialty access, and Medicaid non-coverage makes this alignment particularly difficult.

What to Expect When Starting Rezdiffra in Mississippi

Patients prescribed Rezdiffra in Mississippi should anticipate a 2 to 4 week delay between prescription and first fill due to prior authorization processing. Specialty pharmacies typically require verification of insurance coverage, prior authorization approval, and financial assistance enrollment before dispensing.

The prescribing information specifies dosing based on baseline thyroid-stimulating hormone (TSH): patients with TSH within normal limits start at 80 mg once daily for the first 3 months, then increase to 100 mg daily [9]. Liver function tests (ALT, AST, bilirubin) should be monitored at baseline, 3 months, 6 months, and every 6 months thereafter.

Common adverse reactions in MAESTRO-NASH included diarrhea (27.5% vs. 17.5% placebo), nausea (21.7% vs. 12.3%), and abdominal pain [1]. Mississippi prescribers should also monitor thyroid function, as resmetirom is a selective thyroid hormone receptor beta agonist and can suppress TSH in some patients.

Patients filling Rezdiffra at a Mississippi specialty pharmacy will typically receive 30-day supplies with mandatory refill coordination calls. Missing a refill window can trigger re-authorization requirements with some PBMs, so patients should respond promptly to pharmacy outreach.